ストックスクリーナーアプリを入手
1.60
0.00%
0.00
アフターアワーズ：
1.61
0.01
+0.63%
前日終値:
$1.60
開ける：
$1.58
24時間の取引高:
245.29K
Relative Volume:
0.29
時価総額：
$71.02M
収益：
-
当期純損益:
$-28.54M
株価収益率:
-2.5806
EPS:
-0.62
ネットキャッシュフロー:
$-22.72M
1週間 パフォーマンス:
-2.44%
1か月 パフォーマンス:
-7.51%
6か月 パフォーマンス:
-67.87%
1年 パフォーマンス:
-73.77%
1日の値動き範囲:
$1.58
$1.64
1週間の範囲:
$1.57
$1.69
52週間の値動き範囲:
$1.40
$11.67
Essa Pharma Inc Stock (EPIX) Company Profile
EPIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EPIX
Essa Pharma Inc
|
1.60 | 71.02M | 0 | -28.54M | -22.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-04 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-04 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-11-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2021-03-04 | 開始されました | Piper Sandler | Overweight |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2019-10-25 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Essa Pharma Inc (EPIX) 最新ニュース
Surprising News! ESSA Pharma’s Big Breakthrough Expected Soon. - Jomfruland.net
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit? - Yahoo Finance
ESSA Pharma’s Cash Management: A Potential Risk to Shareholder Value and Market Stability - TipRanks
ESSA Pharma Inc. Reports Strategic Shift Amid Losses - TipRanks
ESSA Pharma: Fiscal Q4 Earnings Snapshot - The Ridgefield Press
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 - Barchart
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
ESSA Pharma (NASDAQ:EPIX) Issues Quarterly Earnings Results - MarketBeat
SEC Form 10-K filed by ESSA Pharma Inc. - Quantisnow
ESSA Pharma Halts Key Cancer Drug Trials, Initiates Strategic Review Amid Clinical Setback - StockTitan
ESSA Pharma ends long-standing license agreement with cancer agencies - Investing.com
ESSA Pharma Inc. Adopts Executive Severance Plan**United States Securities and Exchange Commission Filing – ESSA Pharma Inc. submitted a current report on Form 8-K, dated June 5, 2024, announcing the adoption of the ESSA Pharma Inc. Severance P - Defense World
ESSA Pharma Introduces New Executive Severance Plan - TipRanks
RTW Investments LP Grows Stake in ESSA Pharma Inc. (NASDAQ:EPIX) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc.EPIX - PR Newswire
Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session - MSN
Piper Sandler Downgrades ESSA Pharma (EPIX) - MSN
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Oppenheimer Downgrades ESSA Pharma (EPIX) - MSN
PFM Health Sciences, LP Adjusts Stake in ESSA Pharma Inc - GuruFocus.com
RTW INVESTMENTS, LP Acquires Shares in ESSA Pharma Inc - GuruFocus.com
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
ESSA Pharma And 2 Other US Penny Stocks To Watch - Yahoo Finance
Jones Trading Downgrades ESSA Pharma (EPIX) - MSN
ESSA Pharma (NASDAQ:EPIX) Lowered to Market Perform Rating by Oppenheimer - Defense World
ESSA Pharma (NASDAQ:EPIX) Rating Lowered to Neutral at Piper Sandler - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Growth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock - MarketBeat
Bb biotech ag sells Essa Pharma shares for $12 million - Investing.com
Bb biotech ag sells Essa Pharma shares for $12 million By Investing.com - Investing.com UK
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ESSA Pharma shares downgraded after halting drug development By Investing.com - Investing.com Canada
ESSA Pharma terminates vital trial, leading Piper Sandler to cut shares rating - Investing.com Canada
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials - Investing.com Canada
Jefferies Financial Group Downgrades ESSA Pharma (NASDAQ:EPIX) to Hold - MarketBeat
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect | NDAQ:EPIX | Press Release - Stockhouse Publishing
Michael Jenson, PA-C, on Minnesota Urology’s Surgical Impotence Management Strategy program - Urology Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect - AccessWire
ESSA Pharma tank as it drops Phase II masofaniten study - The Pharma Letter
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
ESSA Pharma stock plunges to 52-week low of $1.55 - Investing.com India
ESSA Pharma stock plunges to 52-week low of $1.55 By Investing.com - Investing.com South Africa
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Essa ends prostate cancer bid, seeks strategic options - BioWorld Online
ESSA Pharma tanks after terminating trial for its prostate cancer treatment - MSN
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results - Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results - Benzinga
ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC - OncLive
Essa Pharma Inc (EPIX) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):